Bionyra Pharma
Developing next-generation biologics for severe immunological and inflammatory diseases
$165MSeries A
Role not disclosedActivity from announced rounds
Developing next-generation biologics for severe immunological and inflammatory diseases
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.